Core Viewpoint - Molina Healthcare, Inc. is under investigation for potential securities fraud and unlawful business practices following disappointing financial results and guidance revisions [1][4]. Financial Performance - On July 7, 2025, Molina reported preliminary adjusted earnings of approximately $5.50 per share and lowered its full-year 2025 adjusted earnings guidance by over 10% to a range of $21.50 to $22.50 per share [3]. - Following this announcement, Molina's stock price decreased by $6.97, or about 2.9%, closing at $232.61 per share [3]. - On July 23, 2025, Molina released finalized second-quarter results, reporting adjusted earnings per diluted share of $5.48, which missed both analyst estimates and prior guidance [4]. - The earnings shortfall was attributed to increased medical cost pressures, including higher utilization of behavioral health, pharmacy, and inpatient/outpatient services [4]. - Molina again revised its full-year guidance downward due to updated information and revised assumptions regarding medical cost trends [4]. - Following the finalized results, Molina's stock price fell by $32.03, or approximately 16.8%, closing at $158.22 per share [5].

Core Viewpoint - A lawsuit has been filed against Flywire Corporation and its senior executives for potential violations of federal securities laws, with claims related to the company's misrepresentation of its revenue growth and the impact of visa-related restrictions on its business [1][2][4]. Group 1: Lawsuit Details - Investors have until September 23, 2025, to request to lead the case, which is pending in the U.S. District Court for the Eastern District of New York [2]. - The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Flywire securities [2]. Group 2: Company Background - Flywire operates as a payments-enablement and software company, primarily serving the education sector, which relies heavily on international enrollments and student preferences [3]. - The company has faced challenges due to tightening student visa and permitting rules implemented by the Canadian and Australian governments in late 2023 and early 2024 [3]. Group 3: Financial Misrepresentation Allegations - Despite facing headwinds, Flywire allegedly overstated the strength and sustainability of its revenue growth while downplaying the negative impacts of permit- and visa-related restrictions [4]. - The lawsuit claims that Flywire's management misrepresented the company's financial condition, leading to significant investor losses [4]. Group 4: Stock Performance - On February 25, 2025, Flywire announced a significant deterioration in its education sector business, citing "double digit declines in student visa issuance" and anticipated continued restrictions [5]. - Following this announcement, Flywire's stock price dropped approximately 37%, from $17.64 per share to $11.05 per share within a day [5].

Core Viewpoint - A lawsuit has been filed against RxSight, Inc. and its senior executives for potential violations of federal securities laws, with claims related to undisclosed challenges in product adoption and a significant decline in stock value following revenue forecast cuts [1][2][4][5][6]. Group 1: Company Overview - RxSight, Inc. specializes in manufacturing light adjustable intraocular lenses for cataract surgery, with its primary product being the Light Adjustable Lens (LAL) that can be customized post-surgery through non-invasive light treatments [3]. Group 2: Legal Proceedings - The lawsuit is pending in the U.S. District Court for the Central District of California, titled Makaveev v. RxSight, Inc., et al., No. 25-cv-01596, with investors having until September 22, 2025, to seek lead plaintiff status [2]. Group 3: Financial Performance and Stock Impact - RxSight experienced a significant decline in stock price, dropping approximately 38% from $26.12 to $16.21 per share on April 3, 2025, after cutting its 2025 revenue forecast due to a market softening noted in the second half of 2024 [5]. - Following a further revenue forecast cut on July 8, 2025, attributed to slower LAL utilization and adoption challenges, the stock price fell again by about 38%, from $12.79 to $7.95 per share on July 9, 2025 [6].

Core Viewpoint - Berger Montague PC is investigating claims against Fiserv, Inc. following a class action lawsuit alleging that the company overstated its growth by not disclosing issues with its Clover payment platform [1][3]. Group 1: Lawsuit Details - The class action lawsuit claims that Fiserv and certain executives failed to disclose that Clover's revenue growth was artificially boosted by forcing merchants to transition from the legacy Payeezy platform [3]. - Investors became aware of Fiserv's true financial situation after the company lowered its 2025 organic growth projections on July 23, 2025, leading to a significant decline in share price [4]. Group 2: Investor Information - Investors who purchased Fiserv securities between July 24, 2024, and July 22, 2025, have until September 22, 2025, to seek appointment as lead plaintiff representatives [2][5].

Contact Us To Participate or Learn More: If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us. The Law Offices of Frank R. Cruz, Email us at: [email protected] Call us at: 310-914-5007 Visit our website at: www.frankcruzlaw.com Follow us for updates on Twitter: twitter.com/FRC_LAW. If you inquire by email, please include your mailing address, telephone number, and number of shares p ...

Core Viewpoint - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Fluor Corporation regarding possible violations of federal securities laws following a significant drop in Fluor's stock price after disappointing financial results and lowered guidance [1][3]. Financial Performance - On August 1, 2025, Fluor Corporation reported its second-quarter financial results and lowered its full-year guidance, attributing the disappointing performance to escalating costs across several infrastructure projects, including subcontractor design errors, increased material prices, and scheduling delays [3]. - Fluor also noted a decline in capital spending among customers, which had not been previously disclosed despite earlier affirmations of its full-year outlook [3]. - Following the announcement, Fluor shares closed down 27.04% on August 1, 2025 [3]. Legal Investigation - Johnson Fistel, PLLP is reaching out to investors who incurred significant losses in Fluor securities to determine eligibility for participation in a potential class action or recovery of losses [2].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Fiserv, Inc. due to allegations of misleading statements and failure to disclose critical issues related to its Clover platform, which has led to significant financial losses for investors [2][4]. Group 1: Allegations Against Fiserv - The complaint alleges that Fiserv and its executives violated federal securities laws by making false and misleading statements regarding the performance and growth of its Clover platform [4]. - Key issues include forced migrations from the older Payeezy platform to Clover, which temporarily inflated Clover's revenue growth and GPV, masking a slowdown in new merchant business [4]. - Following the forced conversions, many former Payeezy merchants switched to competitors due to Clover's high pricing and compatibility issues, leading to a significant slowdown in Clover's GPV growth [4]. Group 2: Market Reaction - On April 24, 2025, Fiserv reported a GPV growth of only 8% for Q1 2025, a decline from 14-17% in 2024, causing the stock to drop 18.5% to $176.90 per share [5]. - On May 15, 2025, Fiserv announced continued deceleration in GPV growth, resulting in a further stock drop of 16.2% to $159.13 per share [5]. - On July 23, 2025, Fiserv lowered its full-year organic growth guidance and reported a deceleration in quarterly organic revenue growth to 9% year-over-year, leading to a stock decline of 13.9% to $143.00 per share [5]. Group 3: Legal Proceedings - Investors who suffered losses exceeding $75,000 in Fiserv between July 24, 2024, and July 22, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal options [1][2]. - The deadline for seeking the role of lead plaintiff in the federal securities class action against Fiserv is September 22, 2025 [2][6]. - Any member of the putative class can move the court to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [6].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against iRobot Corporation due to allegations of misleading statements and failure to disclose critical information regarding the company's financial stability and operations following the termination of the Amazon Acquisition [2][4]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who suffered losses exceeding $50,000 in iRobot between January 29, 2024, and March 11, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against iRobot, with a deadline of September 5, 2025, for investors to seek the role of lead plaintiff [2][6]. - The complaint alleges that iRobot overstated the effectiveness of its Restructuring Plan and failed to disclose doubts about its ability to operate profitably as a standalone company [4]. Group 2: Financial Performance - iRobot reported a loss of $2.06 per share on revenue of $172 million for the fourth quarter of 2024, marking a 44% year-over-year decline [5]. - Following the financial results announcement, iRobot's stock price dropped by $3.255 per share, or 51.58%, closing at $3.055 per share on March 13, 2025 [5]. Group 3: Company Background - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3].

Core Viewpoint - A class action securities lawsuit has been filed against Fiserv, Inc. alleging securities fraud that negatively impacted investors between July 24, 2024, and July 22, 2025 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that Fiserv made false statements regarding its Clover platform, which was forced upon Payeezy merchants due to issues with the older platform [2]. - It is alleged that the revenue growth of Clover was artificially inflated by these conversions, masking a slowdown in new merchant acquisitions [2]. - Following the conversions, many former Payeezy merchants reportedly switched to competitors due to Clover's high pricing and poor customer service [2]. - As a result of these merchant losses, Clover's growth in Gross Payment Volume (GPV) and revenue was said to be unsustainable [2]. - The lawsuit contends that Fiserv's positive statements about Clover's growth strategies and business prospects were materially false and misleading [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified period have until September 22, 2025, to request to be appointed as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - A lawsuit has been filed against Sarepta Therapeutics, Inc. and certain senior executives for potential violations of federal securities laws, particularly concerning the safety claims of their product Elevidys [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, captioned Dolgicer v. Sarepta Therapeutics, Inc., et al., No. 25-cv-05317 [2]. - Investors have until August 25, 2025, to request to be appointed to lead the case [2]. Group 2: Product and Allegations - Sarepta is focused on developing treatments for rare diseases, with Elevidys being its key product for Duchenne muscular dystrophy [3]. - Allegations state that Sarepta misrepresented the safety profile of Elevidys, claiming its benefits outweighed risks, while it is linked to fatal acute liver failure in some patients [3]. Group 3: Stock Performance and Impact - Following the announcement of a patient's death due to acute liver failure on March 18, 2025, Sarepta's stock dropped by $27.81, or over 27%, from $101.35 to $73.54 per share [4]. - A second patient death announcement on June 15, 2025, led to a further decline of $15.24, or more than 42%, from $36.18 to $20.94 per share [4]. - A third patient death related to Elevidys was reported on July 17, 2025, causing the stock to fall more than 40% on July 18, 2025 [5].